Rogers, a maker of circuit materials, surged 10% on better-than-expected earnings guidance, seeing full-year earnings around $3.80 per share versus a FactSet consensus of $3.65. United Therapeutics climbed 15% after a U.S. District Court in Delaware ruled in its favor in a patent dispute against Liquidia, whose shares plunged about 25%. Jabil fell more than 7% despite reporting fiscal fourth-quarter results that beat estimates, with adjusted earnings of $4.40 per share and revenue of $10.62 billion. Moderna declined 7% after Citi downgraded the stock to sell, with a price target 60% below Tuesday’s closing price. FormFactor gained 8% after Deutsche Bank initiated coverage with a buy rating, highlighting its position as the second source of probe cards for Nvidia GPUs at TSMC.
Source: Read the original article
